Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 13/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417016 | 1.00 | CSNK2A1 (0.44) | CSNK2A1CSNK2A2CSNK2BEGFRTDO2 | |
| SCHEMBL6415683 | 0.92 | CSNK2A1 (0.45) | CSNK2A1CSNK2A2CSNK2BEGFRABCG2 | |
| SCHEMBL6415701 | 0.92 | CSNK2A1 (0.45) | CSNK2A1CSNK2A2CSNK2BEGFRABCG2 | |
| SCHEMBL6418314 | 0.90 | MAPT (0.39) | CSNK2A1CSNK2A2CSNK2BEGFRTDO2 | |
| SCHEMBL6418336 | 0.90 | MAPT (0.39) | CSNK2A1CSNK2A2CSNK2BEGFRTDO2 | |
| SCHEMBL6414872 | 0.89 | RPA1 (0.43) | CSNK2A1CSNK2A2CSNK2BEGFRTDO2 | |
| SCHEMBL6431840 | 0.86 | CSNK2A1 (0.46) | CSNK2A1CSNK2A2CSNK2BMAPTSMN1; SMN2 | |
| SCHEMBL6431857 | 0.86 | CSNK2A1 (0.46) | CSNK2A1CSNK2A2CSNK2BMAPTSMN1; SMN2 | |
| SCHEMBL6440251 | 0.84 | TP53 (0.41) | EGFRTDO2ABCG2MAPTSMN1; SMN2 | |
| SCHEMBL6440257 | 0.84 | TP53 (0.41) | EGFRTDO2ABCG2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044270-A1 | OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS | 4SC AG (DE) | 2005-05-19 | — | — | WO | disclosed |
| EP-1529531-A1 | Oxadiazolopyrazine derivatives as pharmaceutically active compounds | 4SC AG (DE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | CSNK2A1 953/4885CSNK2A2 723/4885CSNK2B 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.